Agilent Technologies Heads Into Earnings Report With Strong Growth Projections
Agilent Technologies (NYSE:A) is scheduled to release its quarterly financial results on November 24, 2025, with Wall Street analysts anticipating significant year-over-year growth in both earnings and revenue.
The consensus forecast for earnings per share (EPS) is $1.59, which would represent an 8.9% increase from the corresponding quarter last year. Revenue is projected to reach $1.83 billion, a 7.8% rise from the prior-year period.
Analyst confidence in the company's financial outlook appears firm, as the consensus EPS estimate has remained stable over the last 30 days. Stability in earnings estimates is often viewed as a positive indicator for a stock's short-term price performance.
An examination of Agilent's financial ratios reveals a solid market position. The company's price-to-earnings (P/E) ratio stands at 33.89. Its financial health is further underscored by a debt-to-equity ratio of 0.54 and a current ratio of 2.25, indicating a capacity to meet short-term obligations.
Agilent Technologies operates in the life sciences, diagnostics, and applied chemical markets, providing a range of products and solutions to various industries.
Agilent Technologies, Inc. (A) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.